Please login to the form below

Not currently logged in
Email:
Password:

ischaemic stroke

This page shows the latest ischaemic stroke news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Farxiga scores another FDA fast-track designation

AstraZeneca’s Farxiga scores another FDA fast-track designation

The drug also recently demonstrated impressive results in the phase 3 stroke prevention THALES trial, in which treatment with Brilinta reduced the rate of stroke and death by 17% in patients ... who had previously experienced a minor acute ischaemic

Latest news

  • AstraZeneca’s Brilinta reduces rate of secondary stroke AstraZeneca’s Brilinta reduces rate of secondary stroke

    Patients who had an acute ischaemic stroke or transient ischaemic attack may experience a subsequent, potentially avoidable stroke. ... who have previously experienced an acute ischaemic stroke or TIA based on the THALES trial.

  • AZ says Brilinta hits the mark in new stroke trial AZ says Brilinta hits the mark in new stroke trial

    Results of the phase 3 THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack. ... The currently only approved drug for the

  • AZ says Brilinta hits the mark in diabetic heart disease AZ says Brilinta hits the mark in diabetic heart disease

    The study showed that in diabetics with CAD and no prior history of heart attack or stroke, Brilinta given on top of aspirin therapy achieved a statistically-significant reduction in a ... territory. Meanwhile, next year, AZ is also expecting a phase 3

  • CETP inhibitor class finally dies as Merck abandons anacetrapib CETP inhibitor class finally dies as Merck abandons anacetrapib

    However, Merck's drug missed a key secondary objective, failing to reduce a composite outcome of major atherosclerotic events, which could have resulted from a lack of effect on ischaemic stroke,

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    Bayer and Johnson &Johnson have abandoned a 7, 000-patient trial pitting their novel oral anticoagulant (NOAC) Xarelto against aspirin for ischaemic stroke after conceding it will not meet its objectives. ... with venous thromboembolism (VTE), but a

More from news
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    245. Athersys/ Healios. Licence. Development and commercialisation of cell therapy treatments including MultiStem for the treatment of ischaemic stroke.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    225. Athersys / Chugai. Licence and collaboration Japan. Phase 2 stem cell therapy for treatment of ischaemic stroke.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    Cardiovascular diseases – such as heart attack, stroke, DVT and atrial fibrillation – also present a major problem in Russia, with 46 per cent of self-reported sufferers (39 per cent being diagnosed). ... Analysts predict that ischaemic heart disease

  • e-Detailing options

    Boehringer Ingelheim, via Doctors.net.uk, wished to provide an exceptional stroke resource for doctors. ... Doctors were therefore asked, at the start of the presentation, what they prescribed for patients following a first stroke or transient ischaemic

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....